CorporateInformation.com
 
Company Search:
Advanced Search
 
Featured Products and Services
 
 
Wright Investors Service Perspectives
 
 
 
     
  The Wright Reports site is no longer hosted or operated by Manta. Please review the following:
1. You have been redirected to CorporateInformation.com where you can view Snapshot reports or purchase Wright reports or subscriptions of your choosing.
2. If you were previously linking to Wright Reports please change your links to www.corporateinformation.com
3. If you are a paid subscriber with an active subscription please continue on to the member site: http://member.corporateinformation.com/home.asp
4. For additional information related to CorporateInformation.com please contact help@corporateinformation.com, Contact phone nr to be provided later) 		 
     
 
 
 
United Therapeutics Corporation Company Snapshot
Business Description:
United Therapeutics Corporation operates in the Pharmaceutical preparations sector. United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients. The Company's therapeutic products and product candidates are Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Monoclonal Antibodies (MAb) and Glycobiology Antiviral Agents. It generates revenues from the sale of Remodulin, Tyvaso and Adcirca, which it refers to as its commercial products. As of February 15, 2011, the Company's product portfolio included Remodulin, Tyvaso, Adcirca (tadalafil) Tablets, CardioPAL SAVI and Decipher Monitors, Oral Treprostinil (UT-15C), Ch14.18 MAb, Ch14.18 MAb, Oral Treprostinil, 8H9 MAb, IW001, Miglustat and Other Glycobiology Antiviral Agents. In our complete report available for purchase the company is compared to: Cubist Pharmaceuticals Incorporated, Alexion Pharmaceuticals, Inc. and Medicis Pharmaceutical Corporation.
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
United Therapeutics Corporation
  Stock Performance Chart for United Therapeutics Corporation
 
  Stock Data: Recent Stock Performance:
  Current Price (2/3/2012): 50.21
(Figures in U.S. Dollars)
1 Week 2.6%   13 Weeks 3.5%  
4 Weeks 18.8%   52 Weeks -23.9%  
 
United Therapeutics Corporation Key Data:
  Ticker: UTHR Country: UNITED STATES
  Exchanges: NAS Major Industry: Drugs, Cosmetics & Health Care
    Sub Industry: Ethical Drug Manufacturers
  2010 Sales 603,831,000
(Year Ending Jan 2011).		 Employees: 520
  Currency: U.S. Dollars Market Cap: 2,928,981,320
  Fiscal Yr Ends: December Shares Outstanding: 58,334,621
  Share Type: Common Closely Held Shares: 18,964,655
 
 
Featured Products and Services
  
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.